New Case Studies Confirm Benefits of Clyde’s Assay for Early CV Liability Identification
Gossamer Bio, Inc., one of Clyde’s clients, has recently published a series of case studies to highlight the benefits of hiPSC cardiomyocytes for early identification of a broad set of cardiovascular liabilities. Showcasing the poster at SPS2021, authors Beibei Cai and Kristy D. Bruse presented case studies that support the use of the hiPSC-CM assay as an early screening tool for compound selection.
These case studies show that hiPSC-CM assay can assess drug-induced negative inotropy as well as electrical conduction alterations.
The findings of the studies show that:
Cardiomyocyte (hiPSC-CM) assay employed by Clyde Biosciences Ltd using the CellOPTIQ platform can serve as a reliable functional tool for integrated ion channel activity, which are not detected by single ion channel assays.
Cardiomyocyte assay can be used to predict electrical physiology changes, as well negative ionotropic contractility changes which correlated well with ex vivo and in vivo study results.
Early screening using two concentrations, 3 repeats in Clyde’s Primary Screening cardiomyocyte assay is sufficient to identify potential cardiac liabilities at the hit to lead medicinal chemistry phase.
HiPSC-CMs are translatable to patients while reducing the use of surrogate animal models, thus reducing the use of animals.
You can view the full poster and find more information about the study using the button below.